ERBB2 and breast cancer: The current study showed that the HER2-positive (HR-negative) and TNBC subtypes have higher prediction scores than the HER2-positive (HR-positive) and Luminal (A/B) subtypes, suggesting that the rate of pCR to neoadjuvant T/FAC chemotherapy in breast cancer was correlated with luminal status.